A federal jury ruled May 4 in favor of Ariad Pharmaceuticals Inc. in its patent infringement lawsuit targeting Eli Lilly and Co.’s top-selling osteoporosis drug and a separate sepsis medication.

The U.S. District Court jury in Boston awarded Ariad and three co-plaintiffs, including the Massachusetts Institute of Technology, about $65.2 million. The award includes a 2.3 percent royalty on future U.S. sales of Evista and Xigris until the patent expires in 2019. Last year, the two drugs had combined worldwide sales of about $1.3 billion for the Indianapolis-based company.